利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

215 条记录 (耗时 0.046 秒)

    Combined meningococcal conjugates with common carrier protein
    2.
    发明授权
    Combined meningococcal conjugates with common carrier protein 有权
    联合脑膜炎球菌结合物与普通载体蛋白

    公开(公告)号：US09492558B2

    公开(公告)日：2016-11-15

    申请号：US11587101

    申请日：2005-04-29

    申请人： Paolo Costantino

    发明人： Paolo Costantino

    IPC分类号： A61K47/48 ,  A61K39/095 ,  A61K39/00 ,  A61K39/116

    CPC分类号： A61K47/4833 ,  A61K39/095 ,  A61K39/116 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/6037 ,  A61K2039/70 ,  Y02A50/466

    摘要： Carrier-induced epitopic suppression is of particular concern where multiple conjugates with the same carrier protein are administered simultaneously. To avoid the suppression, the invention minimizes the amount of unconjugated carrier protein in a vaccine. The invention provides a composition for immunizing a patient against a disease caused by Neisseria meningitidis, wherein (1) the composition comprises conjugates for at least two of the four meningococcal serogroups A, C, W135 and Y, where at least two of the conjugates have a common carrier protein; and (2) the composition includes the common carrier in an unconjugated form at less than 10 μg/ml.

    摘要翻译： 载体诱导的表位抑制在与同一载体蛋白的多重缀合物同时施用时尤为重要。 为了避免抑制，本发明使疫苗中未缀合的载体蛋白的量最小化。 本发明提供了用于免疫针对脑膜炎奈瑟氏球菌引起的疾病的组合物，其中（1）组合物包含四种脑膜炎球菌血清群A，C，W135和Y中的至少两种的缀合物，其中至少两种共轭物具有 普通载体蛋白; 和（2）组合物以小于10μg/ ml的不结合形式包含共同的载体。

    TYROSINE LIGATION PROCESS
    9.
    发明申请
    TYROSINE LIGATION PROCESS 有权
    酪氨酸生物过程

    公开(公告)号：US20140141034A1

    公开(公告)日：2014-05-22

    申请号：US14131150

    申请日：2012-07-05

    申请人： Roberto Adamo ,  Martin Allen ,  Francesco Berti ,  Elisa Danieli ,  Qi-Ying Hu

    发明人： Roberto Adamo ,  Martin Allen ,  Francesco Berti ,  Elisa Danieli ,  Qi-Ying Hu

    IPC分类号： A61K47/48

    CPC分类号： A61K47/4833 ,  A61K39/385 ,  A61K47/51 ,  A61K47/54 ,  A61K47/549 ,  A61K47/593 ,  A61K47/62 ,  A61K47/64 ,  A61K47/6415 ,  A61K47/646 ,  A61K2039/505

    摘要： A process is provided for preparing a conjugate of Formula (I-A) or (I) comprising a polypeptide containing n number of tyrosine units, where n is an integer greater than or equal to 1, dispersed within the amino acid chain having and amino terminus end (A1) and an acid terminus end (A2) of the protein or polypeptide and having a weight average molecular weight equal to or greater than 10,000 Daltons (10 kDa), wherein the conjugate comprises a number m of tyrosine conjugates (modified tyrosine residues) as depicted in Formula (I-A) or (I), where m is at least one and is less than or equal to n: where X, Lg, L and R are as defined herein.

    摘要翻译： 提供了一种制备式（IA）或（I）的缀合物的方法，其包含分散在具有氨基酸链的氨基酸链和氨基末端末端的含有n个数量的酪氨酸单元的多肽，其中n为大于或等于1的整数 （A1）和所述蛋白质或多肽的酸性末端（A2），并且具有等于或大于10,000道尔顿（10kDa）的重均分子量，其中所述缀合物包含数量m的酪氨酸缀合物（修饰的酪氨酸残基） 如式（IA）或（I）所示，其中m为至少一个且小于或等于n：其中X，Lg，L和R如本文所定义。

    Synthetic immunogenic glycoconjugate for melanoma immunotherapy
    10.
    发明授权
    Synthetic immunogenic glycoconjugate for melanoma immunotherapy 失效
    用于黑素瘤免疫治疗的合成免疫原性糖缀合物

    公开(公告)号：US08680043B2

    公开(公告)日：2014-03-25

    申请号：US13505844

    申请日：2010-11-04

    申请人： Cristina Nativi ,  Lucio Toma ,  Barbara Richichi ,  Carlotta Lunghi

    发明人： Cristina Nativi ,  Lucio Toma ,  Barbara Richichi ,  Carlotta Lunghi

    IPC分类号： A01N61/00 ,  A61K31/00 ,  A61K38/00 ,  A61K47/48 ,  A61P35/00

    CPC分类号： C07K16/44 ,  A61K47/48092 ,  A61K47/48284 ,  A61K47/4833 ,  A61K47/549 ,  A61K47/643 ,  A61K47/646

    摘要： The present invention refers to compounds of formula (I) as useful melanoma vaccines' active ingredients. As a matter of fact, compounds of formula (1) are immunogenic artificial antigens, mimetics of GM3 and GM3 lactone, well known tumor associated antigens (TAAs). In addition, the present invention refers to specific antibodies for compounds of formula (I) which are able to bind to the TAAs. The hereinabove reported compounds and antibodies are therefore potentially useful respectively for the active and passive immunization against tumors over-expressing GM3 ganglioside, in a preferred embodiment melanoma and colon cancer, and for their diagnosis and prognosis.

    摘要翻译： 本发明涉及作为有效黑素瘤疫苗活性成分的式（I）化合物。 事实上，式（1）化合物是免疫原性人造抗原，GM3和GM3内酯的模拟物，众所周知的肿瘤相关抗原（TAAs）。 此外，本发明涉及能够结合TAA的式（I）化合物的特异性抗体。 因此，上述报道的化合物和抗体可分别用于针对过表达GM3神经节苷脂的肿瘤的主动和被动免疫，在优选实施方案中，黑素瘤和结肠癌，以及它们的诊断和预后。